[go: up one dir, main page]

WO2007117419A3 - Methods and compositions relating to post-prolyl cleaving enzyme inhibitors - Google Patents

Methods and compositions relating to post-prolyl cleaving enzyme inhibitors Download PDF

Info

Publication number
WO2007117419A3
WO2007117419A3 PCT/US2007/008242 US2007008242W WO2007117419A3 WO 2007117419 A3 WO2007117419 A3 WO 2007117419A3 US 2007008242 W US2007008242 W US 2007008242W WO 2007117419 A3 WO2007117419 A3 WO 2007117419A3
Authority
WO
WIPO (PCT)
Prior art keywords
post
enzyme inhibitors
methods
cleaving enzyme
compositions relating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/008242
Other languages
French (fr)
Other versions
WO2007117419A8 (en
WO2007117419A2 (en
Inventor
Sharlene Adams
Michael I Jesson
Glenn T Miller
Paul A Mclean
Barry Jones
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Point Therapeutics Inc
Original Assignee
Point Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Point Therapeutics Inc filed Critical Point Therapeutics Inc
Publication of WO2007117419A2 publication Critical patent/WO2007117419A2/en
Publication of WO2007117419A8 publication Critical patent/WO2007117419A8/en
Publication of WO2007117419A3 publication Critical patent/WO2007117419A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to post-prolyl cleaving enzyme inhibitors in the treatment of proliferative disorders such as cancer.
PCT/US2007/008242 2006-03-31 2007-03-30 Methods and compositions relating to post-prolyl cleaving enzyme inhibitors Ceased WO2007117419A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78782006P 2006-03-31 2006-03-31
US60/787,820 2006-03-31

Publications (3)

Publication Number Publication Date
WO2007117419A2 WO2007117419A2 (en) 2007-10-18
WO2007117419A8 WO2007117419A8 (en) 2008-02-14
WO2007117419A3 true WO2007117419A3 (en) 2008-07-10

Family

ID=38581565

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/008242 Ceased WO2007117419A2 (en) 2006-03-31 2007-03-30 Methods and compositions relating to post-prolyl cleaving enzyme inhibitors

Country Status (1)

Country Link
WO (1) WO2007117419A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105412113B (en) * 2015-11-05 2018-01-09 中国科学院武汉病毒研究所 Pemetrexed disodium or its pharmaceutically acceptable salt are preparing the application in treating or preventing herpesvirus infection medicine
CN105326841B (en) * 2015-11-05 2018-01-09 中国科学院武汉病毒研究所 Raltitrexed or its pharmaceutically acceptable salt are preparing the application in treating or preventing herpesvirus infection medicine
KR102557900B1 (en) 2016-09-07 2023-07-19 트러스티즈 오브 터프츠 칼리지 Combination therapy using an immuno-DASH inhibitor and a PGE2 antagonist
CN110035766B9 (en) * 2016-09-21 2023-12-15 新加坡科技研究局 Methods and compositions for inhibiting skin inflammation and determining susceptibility to cancer
CN107970442A (en) * 2017-12-06 2018-05-01 成都康华生物制品有限公司 A kind of preparation method for adsorbing acellular whooping cough and the bloodthirsty influenza quadrivalent combination vaccine of Type B

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875737B1 (en) * 1996-06-28 2005-04-05 Trustees Of Tufts College Multivalent compounds for crosslinking receptors and uses thereof
US6890904B1 (en) * 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
US7109347B2 (en) * 2001-06-27 2006-09-19 Probiodrug Ag Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875737B1 (en) * 1996-06-28 2005-04-05 Trustees Of Tufts College Multivalent compounds for crosslinking receptors and uses thereof
US6890904B1 (en) * 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
US7109347B2 (en) * 2001-06-27 2006-09-19 Probiodrug Ag Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents

Also Published As

Publication number Publication date
WO2007117419A8 (en) 2008-02-14
WO2007117419A2 (en) 2007-10-18

Similar Documents

Publication Publication Date Title
WO2008076278A8 (en) Methods of cancer treatment with igf1r inhibitors
WO2009099719A3 (en) Compositions and methods for the treatment of tumor of hematopoietic origin
WO2008030883A3 (en) Treatment of cancer
WO2008124660A3 (en) Methods and compositions for the treatment of cancer
WO2006071960A3 (en) Compositions and methods of treating cell proliferation disorders
WO2007011962A3 (en) Treatment of cancer
WO2010074588A8 (en) Pharmaceutical compounds
WO2008128072A3 (en) Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders
WO2008127290A3 (en) Alginate and alginate lyase compositions and methods of use
WO2010002956A3 (en) Heterocyclic derivatives as modulators of ion channels
WO2008014238A3 (en) Dimeric iap inhibitors
WO2007089445A3 (en) Ang2 and vegf inhibitor combinations
WO2007092622A3 (en) Compositions and methods for treating bone
WO2009006577A3 (en) Compositions and methods for inhibiting ezh2
WO2007145704A3 (en) Gemcitabine combination therapy
WO2008086462A3 (en) AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF β-CANTENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS
WO2007127204A3 (en) Methods and compositions relating to immunostimulation
WO2008014229A3 (en) Dimeric iap inhibitors
WO2007140205A3 (en) Methods of treating fibrosis
WO2009064752A3 (en) Heterocyclic derivatives as modulators of ion channels
WO2007081751A9 (en) Compositions and methods for the treatment of cancer
WO2009010787A3 (en) Stable pharmaceutical compositions comprising one or more hmg-coa reductase inhibitors
WO2009009034A3 (en) Methods and compositions useful in the treatment of mucositis
WO2008092099A3 (en) Compositions and methods for treating hematopoietic malignancies
AU2007260950A8 (en) Methods and compositions for targeting HEPSIN

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07754725

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07754725

Country of ref document: EP

Kind code of ref document: A2